Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stallergenes Greer PLC

www.stallergenesgreer.com

Latest From Stallergenes Greer PLC

Stallergenes Greer's Delisting To Focus Leadership On Facility Issues

The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.

 

M & A Immune Disorders

Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO

Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.

 

Clinical Trials Immune Disorders

Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Can Denmark's ALK-Abello Crack The US Allergy Market?

Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.

Business Strategies Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Stallergenes SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Stallergenes Greer PLC
  • Senior Management
  • Fereydoun Firouz, CEO
  • Contact Info
  • Stallergenes Greer PLC
    Phone: (33) 20 7239 4500
    40 Bernard St.
    3rd Floor
    London, WC1N 1LE
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register